It has been approved for the first-line treatment of patients with EGFR-variant advanced NSCLC in China based on the phase 3 AENEAS study.13 The subgroup analysis in patients with baseline brain metastases also showed better intracranial objective response rate (ORR; 62.7% vs 49.1%) and median intracranial progression-free survival (PFS; 29.0 vs 8.3 months; hazard ratio [HR], 0.31 [95% CI, 0.17-0.56]) with aumolertinib compared to gefitinib.14 Here, EGFR is linked to non-small cell lung carcinoma.